Angelini Ventures
Angelini Ventures Backs Hypervision Surgical to Bring AI-Powered Hyperspectral Vision into the Operating Room
Angelini Ventures is participating in the oversubscribed £17 million Series A of Hypervision Surgical, a King's College London spin-out pioneering real-time hyperspectral imaging for surgery.
The round, led by Heal Capital, will accelerate the commercial deployment of Hypervision's Hyperspectral Intelligence® platform — combining proprietary spectral sensing and AI-driven analytics to deliver real-time, quantitative insights into tissue physiology during surgery, with the potential to significantly improve surgical outcomes and patient safety.
As part of the investment, Angelini Ventures Managing Director Tanja Dowe will join Hypervision Surgical's Board of Directors.
We believe Hypervision Surgical is redefining what is possible in surgical visualization. Hypervision's technology has the potential to significantly improve surgical outcomes and patient safety. We are excited to support the team as they scale this breakthrough platform and bring it into clinical practice.
Tanja Dowe,